Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pan-tumor × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 2888 Carcinoma, Non-Small-Cell Lung 2420 Breast Neoplasms 2279 Colorectal Neoplasms 1274 Prostatic Neoplasms 1162 Neoplasm Metastasis 1160 Multiple Myeloma 984 Melanoma 975 Ovarian Neoplasms 892 Lung Neoplasms 828 Recurrence 827 Leukemia, Myeloid, Acute 794 Pancreatic Neoplasms 735 Lymphoma, Non-Hodgkin 678 Lymphoma 638 Stomach Neoplasms 608 Carcinoma, Renal Cell 589 Carcinoma, Hepatocellular 571 Leukemia, Lymphocytic, Chronic, B-Cell 504 Squamous Cell Carcinoma of Head and Neck 484 Lymphoma, Follicular 458 Head and Neck Neoplasms 432 Glioblastoma 424 Lymphoma, Large B-Cell, Diffuse 396 Small Cell Lung Carcinoma 389 Leukemia 380 Triple Negative Breast Neoplasms 378 Advanced Solid Tumors 375 Urinary Bladder Neoplasms 368 Uterine Cervical Neoplasms 364

Interventions

Temozolomide 1 S 1 (combination) 1 Oxaliplatin 1 Nivolumab 1 Capecitabine 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04566380 2025-06-03

ONO-4538 Phase II Rollover Study (ONO-4538-98)

Ono Pharmaceutical Co. Ltd

Phase 2 Recruiting

Pan-tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡